MGMT and neoplasm: • Retrospective• No data on steroid use, MGMT promoter methylation status, and IDH mutation status (patients diagnosed between 2014 and 2018)• 51 (37.8%) did not receive any postoperative treatment• Lymphocyte counts but not neutrophil counts in isolation were prognostic• Multivariate analysis adjusted for age, sex, extent of resection, KPS, tumor grade, and therapy